Ovid Therapeutics Management
Management criteria checks 3/4
Ovid Therapeutics' CEO is Jeremy Levin, appointed in Mar 2015, has a tenure of 9.17 years. total yearly compensation is $2.14M, comprised of 29.3% salary and 70.7% bonuses, including company stock and options. directly owns 5.16% of the company’s shares, worth $11.14M. The average tenure of the management team and the board of directors is 2.8 years and 4.2 years respectively.
Key information
Jeremy Levin
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 29.3% |
| CEO tenure | 9.2yrs |
| CEO ownership | 5.2% |
| Management average tenure | 2.8yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024
Apr 09We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
Nov 10
Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth
Jun 27Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation
Mar 13Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?
Sep 09Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04
Aug 09We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully
Jun 09Ovid Therapeutics: Good Entry Point For Investors
Jun 18Ovid Therapeutics appoints Jeff Rona as CFO
Jun 04Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability
Apr 16Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts
Mar 20Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates
Mar 18We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate
Mar 01Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?
Jan 25Revisiting Ovid Therapeutics
Jan 14Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?
Dec 21Ovid Therapeutics misses goal in Angelman syndrome treatment
Dec 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$625k | -US$52m |
| Sep 30 2023 | n/a | n/a | -US$49m |
| Jun 30 2023 | n/a | n/a | -US$49m |
| Mar 31 2023 | n/a | n/a | -US$51m |
| Dec 31 2022 | US$3m | US$607k | -US$54m |
| Sep 30 2022 | n/a | n/a | -US$68m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$67m |
| Dec 31 2021 | US$847k | US$584k | US$120m |
| Sep 30 2021 | n/a | n/a | US$123m |
| Jun 30 2021 | n/a | n/a | US$117m |
| Mar 31 2021 | n/a | n/a | US$110m |
| Dec 31 2020 | US$2m | US$560k | -US$81m |
| Sep 30 2020 | n/a | n/a | -US$76m |
| Jun 30 2020 | n/a | n/a | -US$76m |
| Mar 31 2020 | n/a | n/a | -US$67m |
| Dec 31 2019 | US$3m | US$530k | -US$60m |
| Sep 30 2019 | n/a | n/a | -US$56m |
| Jun 30 2019 | n/a | n/a | -US$53m |
| Mar 31 2019 | n/a | n/a | -US$53m |
| Dec 31 2018 | US$3m | US$530k | -US$52m |
| Sep 30 2018 | n/a | n/a | -US$50m |
| Jun 30 2018 | n/a | n/a | -US$46m |
| Mar 31 2018 | n/a | n/a | -US$44m |
| Dec 31 2017 | US$2m | US$515k | -US$65m |
Compensation vs Market: Jeremy's total compensation ($USD2.14M) is above average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Jeremy's compensation has been consistent with company performance over the past year.
CEO
Jeremy Levin (70 yo)
9.2yrs
Tenure
US$2,136,546
Compensation
Dr. Jeremy Max Levin, BA Zoology, DPhil, MB BChir, serves as Director of Graviton BioScience Corporation from May 2023. He has been the Chief Executive Officer of Ovid Therapeutics Inc. since March 2015 an...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 9.2yrs | US$2.14m | 5.16% $ 11.1m | |
| Chief Business and Financial Officer | 2.9yrs | US$1.08m | 0.019% $ 42.0k | |
| General Counsel | 5.2yrs | US$1.07m | 0.018% $ 39.5k | |
| Chief Operating Officer | 2.9yrs | US$1.23m | 0.0039% $ 8.4k | |
| Chief Human Resources Officer | 1.8yrs | no data | no data | |
| Senior Vice President of Global Manufacturing & CMC QA | 8.2yrs | US$1.18m | no data | |
| Senior Vice President of Regulatory Affairs | 2.8yrs | no data | no data | |
| Senior Vice President of Clinical Development | 2.8yrs | no data | no data | |
| Chief Strategy Officer | 1.8yrs | no data | no data | |
| Chief Medical Officer | 1.3yrs | no data | no data | |
| Head of Epilepsy Research | 1.3yrs | no data | no data | |
| Chief Scientific Officer | less than a year | no data | no data |
2.8yrs
Average Tenure
55yo
Average Age
Experienced Management: OVID's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.1yrs | US$2.14m | 5.16% $ 11.1m | |
| Chairman of the Scientific & Clinical Advisory Board | 3.1yrs | no data | no data | |
| Independent Director | 6.9yrs | US$86.66k | 0% $ 0 | |
| Lead Independent Director | 8.5yrs | US$104.16k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$79.16k | 0% $ 0 | |
| Member of Scientific & Clinical Advisory Board | 7.3yrs | no data | no data | |
| Member of the Scientific & Clinical Advisory Board | 3yrs | no data | no data | |
| Independent Director | 8.7yrs | US$91.66k | 0.028% $ 61.0k | |
| Independent Director | 2.6yrs | US$71.66k | 0% $ 0 | |
| Member of Scientific & Clinical Advisory Board | 2.8yrs | US$1.59m | no data | |
| Member of Scientific & Clinical Advisory Board | 4.2yrs | no data | no data |
4.2yrs
Average Tenure
67.5yo
Average Age
Experienced Board: OVID's board of directors are considered experienced (4.2 years average tenure).